Multiple Myeloma
August 2017 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Multiple Myeloma abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Multiple Myeloma. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Multiple Myeloma. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Multiple Myeloma every 3 months. Thank you for your ongoing subscription to this publication.

Sincerely,
Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Safety of ixazomib for the treatment of multiple myeloma.
Authors:Bonnet A, Moreau P
Institution:a Department of Hematology , University Hospital Hotel-Dieu , Nantes , France.
Journal:Expert Opin Drug Saf. 2017 Aug;16(8):973-980. doi: 10.1080/14740338.2017.1344212. Epub 2017 Jul 12.

2:Recognition of early mortality in multiple myeloma by a prediction matrix.
Authors:Terebelo H, Srinivasan S, Narang M, Abonour R, Gasparetto C, Toomey K, Hardin JW, Larkins G, Kitali A, Rifkin RM, Shah JJ
Institution:Providence Cancer Center, Southfield, Michigan. Carolina.
Journal:Am J Hematol. 2017 Sep;92(9):915-923. doi: 10.1002/ajh.24796. Epub 2017 Jul 19.

3:How is patient care for multiple myeloma advancing?
Authors:Genadieva Stavric S, Bonello F, Bringhen S, Boccadoro M, Larocca A
Institution:a Medical Faculty , University Hematology Clinic , Skopje , Macedonia. Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino , Torino , Italy. Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino , Torino , Italy. Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino , Torino , Italy. Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino , Torino , Italy.
Journal:Expert Rev Hematol. 2017 Jun;10(6):551-561. doi: 10.1080/17474086.2017.1326814. Epub 2017 May 19.

4:The safety of daratumumab for the treatment of multiple myeloma.
Authors:Cejalvo MJ, Ribas P, de la Rubia J
Institution:a Hematology Service , University Hospital Doctor Peset , Valencia , Spain. "San Vicente Martir" , Valencia , Spain.
Journal:Expert Opin Drug Saf. 2017 Jun;16(6):753-760. doi: 10.1080/14740338.2017.1328053. Epub 2017 May 22.

5:Novel investigational drugs active as single agents in multiple myeloma.
Authors:D'Agostino M, Salvini M, Palumbo A, Larocca A, Gay F
Institution:a Myeloma Unit, Division of Hematology , University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino , Torino , Italy. Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino , Torino , Italy. Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino , Torino , Italy. Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino , Torino , Italy. Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino , Torino , Italy.
Journal:Expert Opin Investig Drugs. 2017 Jun;26(6):699-711. doi: 10.1080/13543784.2017.1324571. Epub 2017 May 8.

6:Immunologic approaches for the treatment of multiple myeloma.
Authors:Rasche L, Weinhold N, Morgan GJ, van Rhee F, Davies FE
Institution:Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA. Electronic address: LRasche@uams.edu. USA. USA. USA. USA.
Journal:Cancer Treat Rev. 2017 Apr;55:190-199. doi: 10.1016/j.ctrv.2017.03.010. Epub 2017 Apr 6.

7:Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses.
Authors:Aguiar PM, de Mendonca Lima T, Colleoni GWB, Storpirtis S
Institution:Department of Pharmacy, University of Sao Paulo, Sao Paulo, Brazil. Electronic address: aguiar.pm@usp.br. University of Sao Paulo, Sao Paulo, Brazil.
Journal:Crit Rev Oncol Hematol. 2017 May;113:195-212. doi: 10.1016/j.critrevonc.2017.03.014. Epub 2017 Mar 16.

8:Long-term stabilisation of myeloma with curcumin.
Authors:Zaidi A, Lai M, Cavenagh J
Institution:Department of Haematology, Barts Health NHS Trust, London, UK.
Journal:BMJ Case Rep. 2017 Apr 16;2017. pii: bcr2016218148. doi: 10.1136/bcr-2016-218148.

9:Which therapies will move to the front line for multiple myeloma?
Authors:Cejalvo MJ, de la Rubia J
Institution:a Hematology Service , University Hospital Doctor Peset , Valencia , Spain. Martir" , Valencia , Spain.
Journal:Expert Rev Hematol. 2017 May;10(5):383-392. doi: 10.1080/17474086.2017.1317589. Epub 2017 Apr 24.

10:Marizomib for central nervous system-multiple myeloma.
Authors:Badros A, Singh Z, Dhakal B, Kwok Y, MacLaren A, Richardson P, Trikha M, Hari P
Institution:M&S Greenebaum Cancer Center, University of Maryland Medical Center, Baltimore, MD, USA. MD, USA. USA. MD, USA. USA.
Journal:Br J Haematol. 2017 Apr;177(2):221-225. doi: 10.1111/bjh.14498.

11:IgM myeloma: A multicenter retrospective study of 134 patients.
Authors:Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM, Gozzetti A, Gustine JN, Hajek R, Hungria V, Jarkovsky J, Jayabalan D, Laubach JP, Lewicka B, Maisnar V, Manasanch EE, Moreau P, Morgan EA, Nahi H, Niesvizky R, Paba-Prada C, Pika T, Pour L, Reagan JL, Richardson PG, Shah J, Spicka I, Vij R, Waszczuk-Gajda A, Gertz MA
Institution:Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. School, Boston, Massachusetts, USA. School, Boston, Massachusetts, USA. School, Boston, Massachusetts, USA. School, Boston, Massachusetts, USA. School, Boston, Massachusetts, USA. Rhode Island, USA. School, Boston, Massachusetts, USA.
Journal:Am J Hematol. 2017 Aug;92(8):746-751. doi: 10.1002/ajh.24753. Epub 2017 May 26.

12:Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.
Authors:Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves WI, Hayman SR, Kapoor P, Kourelis T, Kumar SK, Kyle RA, Lacy MQ, Leung N, Lin Y, Lust JA, Mikhael JR, Reeder CB, Roy V, Russell SJ, Sher T, Stewart AK, Warsame R, Zeldenrust SR, Rajkumar SV, Chanan Khan AA
Institution:Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN. Electronic address: dingli.david@mayo.edu. MN. MN. MN. MN. MN. MN. MN. MN. MN. MN. MN. MN. MN. MN. MN. MN. MN.
Journal:Mayo Clin Proc. 2017 Apr;92(4):578-598. doi: 10.1016/j.mayocp.2017.01.003. Epub 2017 Mar 11.

13:How I manage the toxicities of myeloma drugs.
Authors:Delforge M, Ludwig H
Institution:Department of Hematology, University Hospital Leuven, Leuven, Belgium; and. Oncology, Haematology and Palliative Care, Wilhelminenspital, Vienna, Austria.
Journal:Blood. 2017 Apr 27;129(17):2359-2367. doi: 10.1182/blood-2017-01-725705. Epub 2017 Mar 8.

14:Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma.
Authors:van Beurden-Tan CHY, Franken MG, Blommestein HM, Uyl-de Groot CA, Sonneveld P
Institution:Chrissy H.Y. van Beurden-Tan and Pieter Sonneveld, Erasmus MC Cancer Institute; Margreet G. Franken, Hedwig M. Blommestein, and Carin A. Uyl-de Groot, Erasmus University Rotterdam, Rotterdam; and Hedwig M. Blommestein and Carin A. Uyl-de Groot, Comprehensive Cancer Organisation, Utrecht, the Netherlands. Margreet G. Franken, Hedwig M. Blommestein, and Carin A. Uyl-de Groot, Erasmus University Rotterdam, Rotterdam; and Hedwig M. Blommestein and Carin A. Uyl-de Groot, Comprehensive Cancer Organisation, Utrecht, the Netherlands. Margreet G. Franken, Hedwig M. Blommestein, and Carin A. Uyl-de Groot, Erasmus University Rotterdam, Rotterdam; and Hedwig M. Blommestein and Carin A. Uyl-de Groot, Comprehensive Cancer Organisation, Utrecht, the Netherlands. Margreet G. Franken, Hedwig M. Blommestein, and Carin A. Uyl-de Groot, Erasmus University Rotterdam, Rotterdam; and Hedwig M. Blommestein and Carin A. Uyl-de Groot, Comprehensive Cancer Organisation, Utrecht, the Netherlands. Margreet G. Franken, Hedwig M. Blommestein, and Carin A. Uyl-de Groot, Erasmus University Rotterdam, Rotterdam; and Hedwig M. Blommestein and Carin A. Uyl-de Groot, Comprehensive Cancer Organisation, Utrecht, the Netherlands.
Journal:J Clin Oncol. 2017 Apr 20;35(12):1312-1319. doi: 10.1200/JCO.2016.71.1663. Epub 2017 Feb 27.

15:A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.
Authors:Berenson J, Manges R, Badarinath S, Cartmell A, McIntyre K, Lyons R, Harb W, Mohamed H, Nourbakhsh A, Rifkin R
Institution:Institute for Myeloma and Bone Cancer Research, West Hollywood, California.
Journal:Am J Hematol. 2017 May;92(5):460-466. doi: 10.1002/ajh.24687. Epub 2017 Mar 22.

16:Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes.
Authors:Landgren O, Iskander K
Institution:Myeloma Service, Division of Hematology Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Journal:J Intern Med. 2017 Apr;281(4):365-382. doi: 10.1111/joim.12590. Epub 2017 Feb 16.

17:Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.
Authors:Holstein SA, McCarthy PL
Institution:Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA. Institute, Buffalo, NY, USA. philip.mccarthy@roswellpark.org.
Journal:Drugs. 2017 Apr;77(5):505-520. doi: 10.1007/s40265-017-0689-1.

18:Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy.
Authors:Berdeja JG, Bauer T, Arrowsmith E, Essell J, Murphy P, Reeves JA Jr, Boccia RV, Donnellan W, Flinn I
Institution:Sarah Cannon Research Institute, Nashville, TN, USA.
Journal:Br J Haematol. 2017 Apr;177(2):254-262. doi: 10.1111/bjh.14536. Epub 2017 Feb 7.

19:Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis.
Authors:Hu B, Zhou Q, Wu T, Zhuang L, Yi L, Cao J, Yang X, Wang J
Journal:Int J Clin Pharmacol Ther. 2017 Apr;55(4):329-338. doi: 10.5414/CP202714.

For a FREE PREVIEW of the Medifocus Guidebook on Multiple Myeloma click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Multiple Myeloma click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Multiple Myeloma...
at a Special 20% Discount


Medifocus Guidebook on Multiple Myeloma

Updated: June 21, 2017
188 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Multiple Myeloma is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

MM72577434

Coupon Expires: September 19, 2017



What Our Customers Are Saying...

"The information in your MediFocus Guidebook on Multiple Myeloma was extremely useful. Thank you for providing this service."
K.J.
Milwaukee, Wisconsin


"I purchased the MediFocus Guidebook on Multiple Myeloma for my mother and it was a great help because it helped us to understand more about the disease, the causes, and the treatment options. Although there is no cure, it has helped us cope with the situation and helped us figure out how we can live with the disease."
J.M.
New York, New York


"My oncologist borrowed my copy of the MediFocus Guidebook on Multiple Myeloma and found it very useful in his work. He intends to contact your office."
D.S.
Miami Beach, Florida



  
Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.